The Standard Nitroglycerin Administration Protocol

Nitroglycerin is typically given as a sublingual tablet or spray at a dose of 0.3 to 0.4 mg for acute chest pain, repeated up to three times at five-minute intervals if pain persists. When faster or more precise control is needed, especially in emergency departments and intensive care units, it is delivered intravenously starting at 5 micrograms per minute and titrated upward. That basic framework has been the backbone of angina and acute coronary care for well over a century, but the details of how, when, and why each route is chosen involve more nuance than a single dosing instruction can convey.

How Nitroglycerin Works in the Body

Nitroglycerin is a prodrug, meaning it does not do much on its own. Once inside the body, an enzyme in blood vessel walls converts it into nitric oxide, the molecule that actually causes vessels to relax and widen. That enzyme, aldehyde dehydrogenase-2, breaks down the nitroglycerin molecule and releases nitric oxide in the process. Researchers have observed that without help from the body’s own reducing agents, the enzyme produces only a brief burst of nitric oxide before it essentially stalls out, which is part of why the drug’s effects fade relatively quickly and why tolerance develops with continuous use.¹

The nitric oxide released causes two main effects. First, it relaxes veins throughout the body, which reduces the volume of blood returning to the heart. This is called preload reduction, and it lowers the pressure the heart has to fill against. Second, it relaxes arteries, reducing the resistance the heart pumps against. Early research showed that after nitroglycerin, central aortic pressure dropped substantially even when a reading taken at the arm showed little change, meaning the drug’s effect on arterial resistance is often underestimated by a standard blood pressure cuff.² In one study, aortic systolic pressure fell by an average of 22 mmHg while brachial pressure dropped by only 12 mmHg. This distinction matters clinically because it means nitroglycerin is doing more for the heart than what the monitor on your arm suggests.

The balance between vein relaxation and artery relaxation is not fixed. In people with normal blood pressure and healthy hearts, nitroglycerin primarily reduces preload. But in patients who are hypertensive or have heart failure with stiff arteries, the afterload-reducing effect dominates, and stroke volume can actually increase because the heart is pumping against less resistance.³ This is why nitroglycerin works differently in different people and why the same dose can have dramatically different blood pressure effects depending on the patient’s baseline cardiovascular state.

Sublingual Tablets and Spray

The most familiar form of nitroglycerin is the small tablet placed under the tongue. For acute angina or chest pain, the standard approach is to take one 0.3 to 0.4 mg tablet sublingually, sit or lie down, and wait five minutes. If pain continues, a second tablet can be taken, followed by a third after another five minutes. If chest pain persists after three doses, the situation is treated as a potential heart attack and emergency services should be called. This three-dose, five-minute-interval protocol has been the standard for decades and remains the foundation of angina self-management.

Nitroglycerin spray delivers roughly the same dose as a tablet and is used in the same way: one or two sprays onto or under the tongue, repeated at five-minute intervals. Both the spray and the tablet reach peak vasodilation at about three minutes, though the spray tends to produce measurable effects slightly sooner and sustains them a bit longer.⁴ In hemodynamic studies, the two forms reduce filling pressures at a similar pace, typically reaching significance within one and a half to two minutes.⁵

For many patients, the spray has a practical advantage that has nothing to do with pharmacology: stability. Nitroglycerin tablets are volatile. They lose potency when exposed to heat, light, or air. Kept in a small, amber, tightly capped glass bottle in a cool place, tablets maintain their strength for roughly three to five months if the bottle is opened no more than once a week.⁶ Carried loose in a pill box or pocket, they can degrade within a week. Cotton or paper fillers inside the bottle also absorb the drug and accelerate loss. The spray canister, by contrast, is a sealed pressurized container with a much longer shelf life, and a large-scale study in elderly angina patients found the spray significantly outperformed tablets in speed of pain relief and the proportion of patients who benefited.⁷ Some of that difference likely reflects the fact that many patients carry old or improperly stored tablets without realizing they have lost potency.

Intravenous Nitroglycerin

When sublingual dosing is not enough or the clinical situation demands tight, moment-to-moment control, nitroglycerin is given through an IV line. This is common in emergency departments for acute coronary syndromes, acute heart failure, and hypertensive crises. IV delivery allows clinicians to adjust the dose continuously rather than waiting for another sublingual tablet to dissolve. The pharmacokinetics are more predictable because the drug goes directly into the bloodstream, bypassing the variability of oral absorption.⁸

Standard IV protocols typically start at 5 micrograms per minute and increase by 5 micrograms every three to five minutes until the desired effect is reached. For acute pulmonary edema, the goal is often to bring systolic blood pressure down by about 25% within the first hour.⁹ In practice, dose ceilings vary by institution and clinical context, but rates above 200 micrograms per minute are unusual outside the most severe cases.

One quirk of IV nitroglycerin that many patients and even some newer clinicians do not realize is that the drug sticks to standard polyvinyl chloride (PVC) tubing. The soft plastic in ordinary IV lines absorbs nitroglycerin from the solution, meaning less drug reaches the patient than what the infusion pump is theoretically delivering.¹⁰ The degree of absorption depends on the flow rate and the length of tubing. At low flow rates the loss is substantial; at higher flow rates it matters less because the tubing saturates more quickly. Early research found that flushing the line with a concentrated nitroglycerin solution before starting the actual infusion helped reduce this loss.¹¹ Many hospitals now use non-PVC tubing for nitroglycerin infusions, but where standard PVC sets are still in use, clinicians titrate to clinical effect rather than relying on the pump’s display alone.

Transdermal Patches and the Tolerance Problem

Nitroglycerin patches are designed for longer-term angina prevention rather than acute relief. A patch applied to the skin releases the drug slowly over hours, maintaining a steady blood level. In theory, this sounds ideal. In practice, it introduces a problem that does not arise with occasional sublingual use: tolerance.

Continuous exposure to nitroglycerin causes the body to become progressively less responsive to it. With transdermal patches worn around the clock, tolerance can develop within the first day of application.¹² The standard solution is to build in a nitrate-free interval each day, and the evidence is clear that 10 to 12 hours off the drug is sufficient to maintain its effectiveness. In a controlled study, a 10-hour nitrate-free period fully preserved improvements in exercise time and other measures, while a 4-hour break was essentially useless, with benefits indistinguishable from continuous therapy.¹³ Removing the patch overnight (typically applying it in the morning and taking it off at bedtime) prevents tolerance and has been confirmed by other research showing that continuous 24-hour patch use abolishes the drug’s benefit entirely.¹⁴

The downside of the nitrate-free window is that you are unprotected during those hours. For most patients, nighttime is when physical exertion is lowest and angina risk is at its lowest, making overnight removal a reasonable trade-off. But patients with nocturnal angina or variant (Prinzmetal) angina may need a different schedule or a different drug class entirely. The patch protocol is not one-size-fits-all, even though the general advice to remove it at night is correct for most people.

Who Should Not Take Nitroglycerin

The most well-known contraindication is the combination of nitroglycerin with phosphodiesterase-5 inhibitors, the class that includes sildenafil, tadalafil, and vardenafil. Both drug classes lower blood pressure through overlapping pathways, and the combination can cause a dangerous synergistic drop in both systolic and diastolic pressure.¹⁵ Because of differences in how long these drugs stay active, the safe waiting period before nitroglycerin can be used varies. With sildenafil, the standard recommendation is to wait at least 24 hours. With tadalafil, which has a much longer half-life, the wait is typically 48 hours. This interaction is absolute, not a matter of degree: nitroglycerin is contraindicated, full stop, while a PDE-5 inhibitor is still in the system.

Another frequently cited concern is right ventricular infarction. Textbooks have long taught that giving nitroglycerin to a patient having a heart attack involving the right ventricle can cause severe hypotension because the right heart depends heavily on adequate filling pressure, and nitroglycerin’s preload-reducing effect can cut that off. A meta-analysis of the available evidence, pooling data from over a thousand patients with inferior and right ventricular infarctions who received sublingual nitroglycerin at a standard 400-microgram dose, did not find a statistically significant increase in adverse events, though the confidence interval was wide and the absolute risk was roughly three additional adverse events per hundred patients treated.¹⁶ The evidence is thinner and less definitive than most clinicians assume, but the cautious approach of withholding nitroglycerin in confirmed right ventricular infarction remains standard practice in most guidelines, partly because the consequences of a severe pressure drop in that setting can be catastrophic even if the average risk is modest.

Other contraindications include severe aortic stenosis, hypertrophic obstructive cardiomyopathy, and any situation where blood pressure is already critically low. Nitroglycerin should also be avoided after recent use of riociguat, another drug that works through the nitric oxide pathway.

Nitroglycerin in the Acute Heart Attack Setting

Nitroglycerin relieves angina effectively, but whether it improves survival after a heart attack is a separate and less encouraging question. Large randomized trials conducted in the 1990s found no significant mortality benefit from routine nitroglycerin use in acute myocardial infarction when added to modern treatments. Animal research has raised the additional concern that sustained nitroglycerin exposure during an active infarction may harm heart muscle cells directly, potentially increasing the size of the damage.¹⁷

This does not mean nitroglycerin is abandoned during heart attacks. It is still used to relieve ongoing ischemic chest pain, to control hypertension, and to manage pulmonary congestion. But it is given for symptom control and hemodynamic management, not with the expectation that it will save tissue or reduce mortality. The distinction matters: nitroglycerin is a treatment for how the patient feels and how their circulation is behaving in the moment, not a curative therapy for the infarction itself.

Storing Sublingual Tablets Correctly

Nitroglycerin’s volatility is underappreciated. The molecule readily evaporates, and the amount of drug in each tiny tablet is small enough that even modest losses matter. The standard storage advice is to keep tablets in their original amber glass bottle, tightly capped, and away from heat and light. Refrigeration helps. Each time the bottle is opened, some drug escapes, so opening the bottle repeatedly throughout the day accelerates degradation. Cotton filler, commonly packed in medication bottles, absorbs nitroglycerin and should be removed after the first opening.⁶

A practical test for whether your tablets are still potent: a fresh nitroglycerin tablet placed under the tongue typically produces a slight tingling or burning sensation. If you feel nothing, the tablet may have lost its strength. This is not a foolproof test, but the absence of any sensation after placing a tablet sublingually is a reasonable signal to get a fresh supply, especially if the bottle has been open for several months or stored in a warm location.

Uses Beyond the Heart

Nitroglycerin’s ability to relax smooth muscle extends to applications that have nothing to do with angina or coronary arteries. One of the more established off-label uses is topical nitroglycerin ointment for anal fissures, where the drug relaxes the internal anal sphincter and improves local blood flow to promote healing. Effectiveness is moderate: one study found that nitroglycerin healed about half of acute fissures and about 40% of chronic ones, though headache was reported by three-quarters of patients who responded to treatment.¹⁸ The title of that paper neatly captures the trade-off many patients face.

Topical nitroglycerin has also been investigated for tendon injuries, particularly rotator cuff disease. A Cochrane review found some evidence that it helps patients with acute shoulder symptoms lasting less than a week, but insufficient evidence for longer-term benefit, and headache was again a common side effect that limits the drug’s practical usefulness.¹⁹ The theory behind this use is that nitric oxide promotes collagen synthesis and angiogenesis in tendons, but the clinical evidence has not yet grown strong enough to make this a routine recommendation.

How Nitroglycerin Went From Explosive to Medicine

Nitroglycerin was first synthesized in 1847 by the Italian chemist Ascanio Sobrero, who immediately noticed it caused a violent headache when even a tiny amount touched his tongue.²⁰ That headache, which Sobrero probably cursed, was the first human observation of the drug’s vasodilatory effect. Alfred Nobel, who had studied under the same mentor as Sobrero, recognized the compound’s explosive potential and built the dynamite industry around it. Nobel himself later developed angina and reportedly refused nitroglycerin as treatment, aware of the irony.

The medical use took shape in the 1860s and 1870s. The Scottish physician Lauder Brunton began treating angina patients with amyl nitrite, a related compound, in 1867. The English physician William Murrell then demonstrated that nitroglycerin itself relieved angina, publishing his results in 1879.²¹ Brunton had already noticed that repeated doses of amyl nitrite seemed to work less well over time, an early recognition of nitrate tolerance that would not be fully explained for another century. Nitroglycerin entered the British Pharmacopoeia initially as a treatment for high blood pressure, and its role in angina management grew from there. The fact that the same molecule served as both the world’s most powerful commercial explosive and one of cardiology’s most important drugs made for a story that could not have been scripted, and it took until 1998, when the Nobel Prize in Physiology or Medicine was awarded for the discovery of nitric oxide’s role in the cardiovascular system, for science to fully explain the mechanism Murrell had stumbled onto empirically over a century earlier.